Manuel A. Navia
Corporate Officer/Principal presso AdipoGenix, Inc.
Posizioni attive di Manuel A. Navia
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
AdipoGenix, Inc.
 AdipoGenix, Inc. Pharmaceuticals: MajorHealth Technology AdipoGenix, Inc. develops molecular pharmaceutical products. It offers small molecule pharmaceuticals to treat obesity and its co-morbidities. The firm’s technology includes AdipoBASE, AdipoSCREEN, AdipoPATH and AdipoTARGET. The company was founded by Gerri Waloga, Barbara E. Corkey, Stephen R. Farmer, James A. Hamilton, James L. Kirkland, H. Jeff Leighton and Paul F. Pilch in 1997 and is headquartered in Boston, MA. | Corporate Officer/Principal | 23/05/2011 | - |
| Direttore/Membro del Consiglio | - | 23/05/2011 |
Storia della carriera di Manuel A. Navia
Precedenti posizioni note di Manuel A. Navia
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Access BridgeGap Ventures
 Access BridgeGap Ventures Investment ManagersFinance Founded in 2011, Access BridgeGap Ventures is a venture capital firm located in Cambridge, Massachusetts. The firm is the life sciences venture capital investment arm of Access Industries, Inc. | Corporate Officer/Principal | - | 10/10/2013 |
Essential Therapeutics, Inc.
 Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections | Direttore Tecnico/Scientifico/R&S | 01/01/2001 | 01/03/2003 |
Althexis Co., Inc.
 Althexis Co., Inc. Miscellaneous Commercial ServicesCommercial Services Althexis Co., Inc. researches and develops drugs for the treatment of human diseases. The company is based in Waltham, MA. Mass. The company was founded by Manuel A. Navia, Paul J. Althexis Co. was acquired by Essential Therapeutics, Inc. on October 25, 2001 for $18.84 million. | Fondatore | 01/01/2001 | 01/01/2001 |
| Presidente | - | 01/01/2001 | |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01/01/1989 | 01/01/1997 |
Altus Pharmaceuticals, Inc.
 Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | Direttore/Membro del Consiglio | 01/01/1992 | - |
| Fondatore | 01/01/1992 | - | |
| Independent Dir/Board Member | 01/01/1992 | - | |
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston. | Investitore di Private Equity | - | 02/06/2011 |
| Corporate Officer/Principal | 02/06/2011 | - |
Formazione di Manuel A. Navia
| The University of Chicago | Doctorate Degree |
| New York University | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 10 |
Posizioni
| Corporate Officer/Principal | 4 |
| Director/Board Member | 2 |
| Founder | 2 |
Settori
| Health Technology | 5 |
| Finance | 3 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| Aziende private | 6 |
|---|---|
Oxford Bioscience Partners
Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston. | Finance |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | Health Technology |
AdipoGenix, Inc.
AdipoGenix, Inc. Pharmaceuticals: MajorHealth Technology AdipoGenix, Inc. develops molecular pharmaceutical products. It offers small molecule pharmaceuticals to treat obesity and its co-morbidities. The firm’s technology includes AdipoBASE, AdipoSCREEN, AdipoPATH and AdipoTARGET. The company was founded by Gerri Waloga, Barbara E. Corkey, Stephen R. Farmer, James A. Hamilton, James L. Kirkland, H. Jeff Leighton and Paul F. Pilch in 1997 and is headquartered in Boston, MA. | Health Technology |
Essential Therapeutics, Inc.
Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections | Health Technology |
Althexis Co., Inc.
Althexis Co., Inc. Miscellaneous Commercial ServicesCommercial Services Althexis Co., Inc. researches and develops drugs for the treatment of human diseases. The company is based in Waltham, MA. Mass. The company was founded by Manuel A. Navia, Paul J. Althexis Co. was acquired by Essential Therapeutics, Inc. on October 25, 2001 for $18.84 million. | Commercial Services |
Access BridgeGap Ventures
Access BridgeGap Ventures Investment ManagersFinance Founded in 2011, Access BridgeGap Ventures is a venture capital firm located in Cambridge, Massachusetts. The firm is the life sciences venture capital investment arm of Access Industries, Inc. | Finance |
- Borsa valori
- Insiders
- Manuel A. Navia
- Esperienza
